Press release
Global NTM Infections Pipeline Poised for Growth as Breakthrough Therapies Advance Toward Late-Stage Development, states DelveInsight
NTM Infections Pipeline
Key Nontuberculous Mycobacterial Infections Companies include Insmed Incorporated, Savara Inc, Paratek Pharmaceuticals Inc, LigaChem Biosciences, Spero Therapeutics, Mannkind Corporation, Pfizer, Agouron Pharmaceuticals, Pharmacia, Janssen Pharmaceutical K.K., and others.
According to DelveInsight's evaluation, the global Nontuberculous Mycobacterial (NTM) Infections pipeline includes 10+ leading companies actively engaged in advancing more than 10 therapeutic candidates. The analysis highlights ongoing progress in clinical trials, therapeutic approaches, mechanisms of action, routes of administration, and developmental milestones.
DelveInsight's report, "Nontuberculous Mycobacterial Infections Pipeline Insight, 2025" , provides a detailed overview of the current clinical landscape and future opportunities within the NTM Infections market.
Request for sample page @ Nontuberculous Mycobacterial Infections Pipeline Outlook [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
What Are the Key Highlights from the NTM Infections Pipeline Report?
* Several Nontuberculous Mycobacterial (NTM) Infection companies worldwide are consistently working to develop innovative therapies for NTM infections, with notable advancements in recent years.
* Key Nontuberculous Mycobacterial Infections Companies include Insmed Incorporated, Savara Inc, Paratek Pharmaceuticals Inc, LigaChem Biosciences, Spero Therapeutics, Mannkind Corporation, Pfizer, Agouron Pharmaceuticals, Pharmacia, Janssen Pharmaceutical K.K., and others.
* Prominent Nontuberculous Mycobacterial (NTM) Infections emerging therapies include ALIS, Antimycobacterial regimen, Omadacycline Oral Tablet, Delpazolid, SPR720, Clofazimine Inhalation Suspension, Ethambutol hydrochloride, Nelfinavir mesylate, Bedaquiline, and more - expected to significantly influence the NTM Infections market.
* In April 2025, MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocrine and orphan lung diseases, announced today that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application for MNKD-101 (Clofazimine Inhalation Suspension), enabling the initiation of a Phase 3 study for the treatment of nontuberculous mycobacterial (NTM) lung disease.
* In April 2025, Beyond Air, Inc. (NASDAQ: XAIR) ("Beyond Air" or the "Company"), a commercial-stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives of patients, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 12,274,830. The issued patent gives the Company protection for its method of delivering gaseous nitric oxide (gNO) to a patient that has a condition associated with non-tuberculous mycobacteria (NTM) lung infection.
* In January 2025, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx"688373.SH) announced that MRX-5, its self-developed anti-infection drug, has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Administration (FDA) for the treatment of non-tuberculous mycobacteria (NTM) infections. This designation marks a significant milestone for MicuRx in the field of NTM infection treatment.
* November 2024: Paratek Pharmaceuticals announced positive topline Phase IIb data for Nuzyra (omadacycline) in NTM pulmonary disease, showing greater than or equal to 50% symptom improvement from baseline.
* October 2024: Spero Therapeutics reported interim Phase 2a results of SPR720 , demonstrating antimicrobial activity but also raising safety concerns at higher doses, which led to a temporary halt in its development strategy.
What Are Nontuberculous Mycobacterial (NTM) Infections?
NTM Infections are caused by diverse environmental mycobacteria - excluding Mycobacterium tuberculosis and Mycobacterium leprae - commonly found in soil, dust, and water. These infections predominantly affect the lungs but may also involve skin, lymph nodes, and other organs, especially in immunocompromised patients.
While not contagious, NTM Infections are chronic and difficult to treat. Symptoms such as persistent cough, weight loss, fatigue, and breathlessness often mimic tuberculosis or other lung conditions. Diagnosis typically involves sputum cultures, imaging, and molecular testing.
Major causative species include Mycobacterium avium complex (MAC) and Mycobacterium abscessus. Treatment generally requires prolonged multi-drug antibiotic regimens extending over a year, with resistance posing major challenges. Rising prevalence is linked to better diagnostics, increased awareness, and aging populations.
Get a Free Sample PDF Report to know more about Nontuberculous Mycobacterial Infections Pipeline Therapeutic Assessment-Nontuberculous Mycobacterial Infections Clinical Trial Assessment [https://www.delveinsight.com/report-store/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Which Nontuberculous Mycobacterial Infections Emerging Therapies Are Under Development?
* ALIS - Insmed Incorporated
* Antimycobacterial regimen - Savara Inc
* Omadacycline Oral Tablet - Paratek Pharmaceuticals Inc
* Delpazolid - LigaChem Biosciences, Inc.
* SPR720 - Spero Therapeutics
* Clofazimine Inhalation Suspension - Mannkind Corporation
* Ethambutol hydrochloride - Pfizer, Pharmacia
* Nelfinavir mesylate - Agouron Pharmaceuticals
* Bedaquiline - Janssen Pharmaceutical K.K.
How Are Nontuberculous Mycobacterial Infection Therapies Being Administered?
Pipeline therapies are being evaluated across multiple routes of administration (ROA):
* Oral
* Parenteral
* Intravenous
* Subcutaneous
* Topical
What Types of Molecules Are in Development?
Therapies fall under various molecular categories, including:
* Small molecules
* Monoclonal antibodies
* Peptides
* Polymers
* Gene therapies
Further Nontuberculous Mycobacterial Infections product details are provided in the report. Download the Nontuberculous Mycobacterial Infections pipeline report to learn more about the emerging Nontuberculous Mycobacterial Infections therapies at:Nontuberculous Mycobacterial Infections Drugs and Therapies [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
Nontuberculous Mycobacterial Infections Therapeutic Assessment
How Is the Nontuberculous Mycobacterial Infections Pipeline Being Assessed?
* By product type and stage of development (early, mid, late phase)
* By route of administration
* By molecular type
* Active vs. inactive (discontinued/dormant) projects
* Collaborative and licensing activities
What Factors Are Driving the NTM Infections Market?
* Rising incidence of NTM infections
* Advancements in diagnostic methods
* Increasing awareness and screening initiatives
* Growing elderly and immunocompromised populations
* Expanding pipeline and ongoing R&D investments
What Barriers Are Hindering Market Growth?
* Limited available treatment options
* Long and costly treatment regimens
* Side effects from prolonged antibiotic use
* Resistance to current therapies
* Low commercial interest and regulatory hurdles
Download Sample PDF Report to know more about Nontuberculous Mycobacterial Infections drugs and therapies -Nontuberculous Mycobacterial Infections Clinical Trial and FDA Approvals [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
What Is the Scope of the Nontuberculous Mycobacterial Infections Pipeline Report?
* Coverage: Global
* Key Nontuberculous Mycobacterial Infections Companies: Insmed Incorporated, Savara Inc, Paratek Pharmaceuticals Inc, LigaChem Biosciences, Inc., Spero Therapeutics, Mannkind Corporation, Pfizer, Agouron Pharmaceuticals, Pharmacia, Janssen Pharmaceutical K.K., and others
* Key Nontuberculous Mycobacterial Infections Therapies: ALIS, Antimycobacterial regimen, Omadacycline Oral Tablet, Delpazolid, SPR720, Clofazimine Inhalation Suspension, Ethambutol hydrochloride, Nelfinavir mesylate, Ethambutol hydrochloride, Bedaquiline, and others
* Nontuberculous Mycobacterial Infections Therapeutic Assessment: Nontuberculous Mycobacterial Infections current marketed and Nontuberculous Mycobacterial Infections emerging therapies
* Nontuberculous Mycobacterial Infections Market Dynamics: Nontuberculous Mycobacterial Infections market drivers and Nontuberculous Mycobacterial Infections market barriers
Download sample report to make informed decisions - Nontuberculous Mycobacterial Infections Pipeline Assessment [https://www.delveinsight.com/sample-request/nontuberculous-mycobacterial-infections-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=global-ntm-infections-pipeline-poised-for-growth-as-breakthrough-therapies-advance-toward-latestage-development-states-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/primary-research-services
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Global NTM Infections Pipeline Poised for Growth as Breakthrough Therapies Advance Toward Late-Stage Development, states DelveInsight here
News-ID: 4280975 • Views: …
More Releases from ABNewswire
Sickle Cell Disease Market Analysis Report 2034: Pipeline Breakthroughs, Market …
Key Sickle Cell Disease companies include Cellectis, Sana Biotechnology, Global Blood Therapeutics, Inc., CSL Behring, Pfizer, Aruvant Sciences, Graphite Bio, Novartis, Agios Pharmaceuticals, Forma Therapeutics, Vertex Pharmaceuticals, Global Blood Therapeutics, Inc., Alfasigma, Novo Nordisk, bluebird bio, ExCellThera, Gamida Cell, KM Biologics/Takeda, Editas Medicine, and others.
The Sickle Cell Disease (SCD) market across the six major markets (6MM) was valued at approximately USD 650 million in 2023. In 2023, the United States…
Dry Eye Disease Market Size was ~USD 3.76 Billion in 2023 and expected to Grow b …
Key Dry Eye Disease companies developing novel therapies include Palatin Technologies, Aldeyra Therapeutics, ReGenTree/RegeneRx, Mimetogen, Alcon/Aerie, BRIM Biotechnology, Seikagaku, Mitotech, Senju Pharmaceutical, Sylentis/PharmaMar, Stuart Therapeutics, VivaVision Biotech, HanAll/Daewoong, Redwood Pharma, OKYO Pharma, Glaukos, Oculis, and others.
In 2023, the Dry Eye Disease (DED) market size across the 7MM reached approximately USD 3.76 billion, with the United States leading at USD 2.74 billion and an estimated 22.5 million diagnosed cases. Both prevalence…
WECENT Announces Availability of the Original Dell PowerEdge R660 Rack Server, D …
WECENT, a global supplier of enterprise IT equipment and authorized distributor for leading brands including Dell, Lenovo, Huawei, HPE, and Cisco, today announced the official availability of the Original Dell PowerEdge R660 Rack Server [https://www.szwecent.com/product/original-dell-poweredge-r660-rack-server/], a next-generation 1U platform engineered for high-performance computing in space-constrained data center environments.
Designed for organizations requiring powerful compute density, fast memory throughput, and flexible storage capacity, the Dell PowerEdge R660 brings breakthrough capabilities to virtualization…
Elite RF: Engineering the Future of High-Power RF Amplifiers for Defense, Radar, …
Elite RF is advancing high-power, solid-state RF amplifier technology across defense, radar, communications, and industrial applications with fast customization, robust engineering, and a culture of quality.
Image: https://www.abnewswire.com/upload/2025/11/56a063e46377d6a57a92cb4a3bb681d5.jpg
In the world of high-power RF amplifiers, few names stand out like Elite RF. What began in 2014 as a small engineering venture led by a few former Motorola experts has turned into one of the most respected solid-state RF and microwave companies in…
More Releases for Infection
Growing Hospital-Acquired Infection Rates Boost Demand For Infection Prevention …
The Infection Prevention Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].
What Is the Projected Growth of the Infection Prevention Market?
In the past few years, there has been a consistent increase in the size of the infection prevention market. It is predicted that this market…
Prominent Infection Prevention Market Trend for 2025: Strategic Staffing Innovat …
What Are the Projected Growth and Market Size Trends for the Infection Prevention Market?
The infection prevention market is expected to grow from $43.4 billion in 2024 to $45.01 billion in 2025, reflecting a CAGR of 3.7%. Growth drivers include increasing awareness of healthcare-associated infections (HAIs), stringent regulatory guidelines, technological advancements, and globalization.
The Infection Prevention market is expected to grow to $52.2 billion by 2029 at a CAGR of 3.8%, driven…
Yeast Infection Treatment Market Report 2024 - Yeast Infection Treatment Market …
"The Business Research Company recently released a comprehensive report on the Global Yeast Infection Treatment Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
According to The Business Research Company's, The yeast infection…
Combating Infection: Nontuberculous Mycobacterial Infection Market Analysis 2024 …
The nontuberculous mycobacterial infection market size has grown strongly in recent years. It will grow from $13.43 billion in 2023 to $14.25 billion in 2024 at a compound annual growth rate (CAGR) of 6.1%. The growth in the historic period can be attributed to improved diagnostics, aging population, cystic fibrosis awareness, immunosuppressive medications.
The nontuberculous mycobacterial infection market size is expected to see strong growth in the next few…
Infection Surveillance Solutions Market: Empowering Infection Prevention | BD, B …
Allied Market Research analysts have recently introduced a new research study titled "Infection Surveillance Solutions Market- Global Outlook and Forecast 2023-2030." The report offers detailed insights and highlights key players in the industry, including Atlas Medical Software, Becton, Dickinson and Company, Baxter International, GOJO Industries, Deb Group, RL Solutions, HyGreen, Wolters Kluwer, Premier, and Truven Health Analytics. This comprehensive study provides in-depth and clear analysis, encompassing market definitions, classifications, manufacturing…
Infection Prevention & Control Market 2026: Product Overview and Scope of Infect …
Infection Prevention & Control Market Research Report and Forecast to 2019-2026 Report provide an extensive research on the fast-evolving Infection Prevention & Control Market. It also gives competitive landscape of the leading companies with regional and Global analysis of the market till 2026.
The report mainly studies the size, recent trends and development status of the Infection Prevention & Control market, as well as investment opportunities, government policy, market dynamics (drivers,…
